A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)

PURPOSE: This study aimed to evaluate the maximum tolerated dose (MTD) and recommended phase II dose (RPTD), as well as the safety and tolerability of PF-03446962, a monoclonal antibody targeting activin receptor like kinase 1 (ALK-1), in combination with regorafenib in patients with refractory meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Clarke, Jeffrey Melson, Blobe, Gerard C., Strickler, John H., Uronis, Hope Elizabeth, Zafar, S. Yousuf, Morse, Michael, Dropkin, Evan, Howard, Leigh, O’Neill, Margot, Rushing, Christel N., Niedzwiecki, Donna, Watson, Hollie, Bolch, Emily, Arrowood, Christy, Liu, Yingmiao, Nixon, Andrew B., Hurwitz, Herbert I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769092/
https://www.ncbi.nlm.nih.gov/pubmed/31444620
http://dx.doi.org/10.1007/s00280-019-03916-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769092/
https://www.ncbi.nlm.nih.gov/pubmed/31444620
http://dx.doi.org/10.1007/s00280-019-03916-0

Ejemplares similares